Rituximab in neurological disease: principles, evidence and practice
DH Whittam, EC Tallantyre, S Jolles, S Huda… - Practical …, 2019 - pn.bmj.com
Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in
neurological disorders and there are no treatment guidelines. However, as a rapidly acting …
neurological disorders and there are no treatment guidelines. However, as a rapidly acting …
[HTML][HTML] What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
SHM Hamid, D Whittam, K Mutch, S Linaker… - Journal of …, 2017 - Springer
Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been described in
patients with neuromyelitis optica spectrum disorders (NMOSD) without aquaporin-4 …
patients with neuromyelitis optica spectrum disorders (NMOSD) without aquaporin-4 …
Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients
DH Whittam, A Cobo-Calvo… - Multiple sclerosis and …, 2020 - Elsevier
Objective To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse
rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) …
rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) …
Interleukin-6 receptor blockade in treatment-refractory MOG-IgG–associated disease and neuromyelitis optica spectrum disorders
M Ringelstein, I Ayzenberg, G Lindenblatt… - Neurology …, 2021 - AAN Enterprises
Background and Objectives To evaluate the long-term safety and efficacy of tocilizumab
(TCZ), a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte …
(TCZ), a humanized anti–interleukin-6 receptor antibody in myelin oligodendrocyte …
Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
Pathogenic antibodies targeting the aquaporin-4 water channel on astrocytes are
associated with relapsing inflammatory neuromyelitis optica spectrum disorders. The clinical …
associated with relapsing inflammatory neuromyelitis optica spectrum disorders. The clinical …
Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
Objective To define the frequency, duration, and severity of intractable nausea, vomiting, or
hiccups in aquaporin-4–immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica …
hiccups in aquaporin-4–immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica …
What's new in neuromyelitis optica? A short review for the clinical neurologist
D Whittam, M Wilson, S Hamid, G Keir, M Bhojak… - Journal of …, 2017 - Springer
The evolution of neuromyelitis optica spectrum disorder (NMOSD) from a rare, incurable and
misunderstood disease with almost universally poor outcomes to its present state in just over …
misunderstood disease with almost universally poor outcomes to its present state in just over …
Rituximab abrogates aquaporin-4–specific germinal center activity in patients with neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSDs) are caused by immunoglobulin G (IgG)
autoantibodies directed against the water channel aquaporin-4 (AQP4). In NMOSDs …
autoantibodies directed against the water channel aquaporin-4 (AQP4). In NMOSDs …
Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review
JL Chamberlain, S Huda, DH Whittam, M Matiello… - Journal of …, 2021 - Springer
The complement system is a powerful member of the innate immune system. It is highly
adept at protecting against pathogens, but exists in a delicate balance between its protective …
adept at protecting against pathogens, but exists in a delicate balance between its protective …
Predictors of relapse in MOG antibody associated disease: a cohort study
S Huda, D Whittam, R Jackson, V Karthikeayan… - BMJ open, 2021 - bmjopen.bmj.com
Objective To identify factors predictive of relapse risk and disability in myelin
oligodendrocyte glycoprotein associated disease (MOGAD). Setting Patients were seen by …
oligodendrocyte glycoprotein associated disease (MOGAD). Setting Patients were seen by …